Core Insights - The healthcare industry is transitioning towards decentralized, patient-centric care models, with home infusion and specialty pharmacy services emerging as key growth areas [1] - BrightSpring Health Services (BTSG) and Option Care Health (OPCH) are two notable players capitalizing on the demand for cost-effective, high-quality treatment options [1] BrightSpring Health Services (BTSG) - BTSG achieved a remarkable 33% year-over-year growth in its infusion and specialty pharmacy segment in Q1 2025, driven by a 20% increase in prescription volumes and the launch of 127 limited distribution drugs [2][6] - The company reported operational excellence with a dispense accuracy of 99.999%, 95% infusion satisfaction, and over 90% home health satisfaction [7] - Adjusted EBITDA improved by 28% in Q1, with Pharmacy Solutions contributing 31% growth, supported by rising script volumes and operational initiatives [8] - Management raised the 2025 revenue guidance to between $12.0 billion and $12.5 billion, with adjusted EBITDA projected to be between $570 million and $585 million, indicating a potential growth of up to 27% [9][10] - The Zacks Consensus Estimate suggests an 82.1% improvement in BTSG's 2025 earnings per share (EPS) compared to 2024 [14] Option Care Health (OPCH) - OPCH reported a 16% year-over-year revenue growth in Q1, with mid-teens growth in acute therapies and high-teens growth in chronic, rare, and orphan therapies [11] - The company is leveraging AI and robotic process automation (RPA) to enhance operational efficiency and margin expansion [12] - Adjusted EBITDA improved by 13.7% year-over-year, leading to an 8.4% EBITDA margin, while the company repurchased $100 million in stock in Q1 [13] - OPCH's full-year 2025 revenue guidance is set between $5.4 billion and $5.6 billion, with EBITDA projected at $455 million to $470 million [13] - The Zacks Consensus Estimate indicates a 36.6% improvement in OPCH's 2025 EPS over the previous fiscal year [16] Comparative Analysis - BTSG is trading at a forward price-to-sales ratio of 0.31X, above its one-year median of 0.25X, while OPCH is at 0.90X, below its 5-year median of 0.97X, indicating that BTSG is more attractively valued relative to its growth [17] - Recommendations suggest buying BTSG due to its faster revenue and EBITDA growth, while holding OPCH as it makes strategic advancements [18]

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Management L.P. ("Prospect"), investment adviser to Prospect Capital Corporation (NASDAQ: PSEC) and other funds, announced today that Prospect has received an Honorable Mention in Mergers & Acquisitions' 2025 Middle-Market Deals of the Year Awards for Prospect's role in providing value-added capital to Druid City Infusion ("Druid City"). The recognition highlights Prospect's role as a significant capital provider and lender in the transaction, whic ...

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Management L.P. (“Prospect”), investment adviser to Prospect Capital Corporation (NASDAQ: PSEC) and other funds, announced today that Prospect has received an Honorable Mention in Mergers & Acquisitions’ 2025 Middle-Market Deals of the Year Awards for Prospect's role in providing value-added capital to Druid City Infusion ("Druid City"). The recognition highlights Prospect’s role as a significant capital provider and lender in the transaction, whic ...

Option Care Health (OPCH) Q1 2025 Earnings Call April 29, 2025 08:30 AM ET Company Participants Nicole Maggio - SVP & Corporate ControllerJohn Rademacher - CEO & PresidentMike Shapiro - Chief Financial OfficerLisa Gill - Managing DirectorConstantine Davides - Managing DirectorJack Slevin - VP - Healthcare Services Equity ResearchA.J. Rice - Managing Director Conference Call Participants Pito Chickering - AnalystDavid Macdonald - AnalystMatt Larew - Research Analyst - HealthcareJoanna Gajuk - Analyst Operato ...

Option Care Health (OPCH) Q4 2024 Earnings Call February 26, 2025 08:30 AM ET Company Participants Nicole Maggio - SVP & Corporate ControllerJohn Rademacher - CEO, President & DirectorMike Shapiro - Chief Financial OfficerLisa Gill - Managing DirectorConstantine Davides - Managing DirectorSarah Conrad - Global Investment Research Associate Conference Call Participants Matt Larew - Research Analyst - HealthcareBrian Tanquilut - Equity Research Analyst - Healthcare ServicesPito Chickering - AnalystJoanna Gaju ...